(Reuters) - The U.S. Food and Drug Administration is likely to approve Novo Nordisk’s new drug to treat obesity this year, analysts said after wide expectations of an FDA decision late on Monday were not met.
Danish drugmaker Novo Nordisk applied for approval for liraglutide, under the name of Saxenda, on Dec. 20 last year. Monday, exactly 10 months after the filing, was seen by analysts as a deadline for a decision from FDA about approval.[ID:nWEB00G4Y]
Help employers find you! Check out all the jobs and post your resume.
